OS Therapies Incorporated (OSTX)

OS Therapies Accepts New FDA Meeting Request to Review Biomarker Data as Part of BEST Program

CDER meeting expected to take place in the summer of 2026 in parallel with CBER's Type B Statistical Methods...

Form 8-K/A - Current report: [Amend]

OS Therapies Third Quarter 2026 Corporate Outlook

Upcoming Type B Statistical Methods Meeting expected to set stage for FDA to align with EMA and MHRA on use of...

Form 8-K - Current report

OS Therapies Appoints Dr. Craig Eagle to Board of Directors

Company secures $10 million line of credit supported by OS Therapies UK tax creditsNew York, New York and...

OS Therapies Provides U.S. Regulatory Update

Type B Meeting requested to follow up on September 2025 End of Phase 2 FDA Meeting guidance on statistical...

OS Animal Health Announces Peer-Reviewed Publication of Clinical Trial Data for OST-HER2 Plus Palliative Radiation as Frontline Treatment in Canine Osteosarcoma

20% of OST-HER2 treated dogs survived 2-year vs. 1% in control group (p = 0.00995)Over 15,000 dogs per year...

OS Therapies Achieves Global Regulatory Alignment on Design of Phase 3 Trial of OST-HER2 in Fully Resected, Pulmonary Metastatic Osteosarcoma

Confirmatory Phase 3 trial to commence prior to BLA grant under Accelerated Approval Program in the U.S. and...

OS Therapies Achieves Statistically Significant 2.5-Year Overall Survival in Phase 2b Trial of OST-HER2 in Fully Resected Pulmonary Metastatic Osteosarcoma

75% 2.5-year overall survival for OST-HER2 vs. 47% pooled historical control (p = 0.003), with no new patient...

OS Therapies Announces the Publication of Four Articles on OST-HER2 and Osteosarcoma in Drug Discovery World

The Company confirms that it will release 2.5 year overall survival data from Phase 2b clinical trial OST-HER2...

OS Therapies to Attend Upcoming Medical, Financial and Industry Conferences

ASCO 2026: 2.5-Year Overall Survival DataJefferies Healthcare Conference: Partnering & Investor meetingsBIO...

OS Therapies Reports First Quarter 2026 Financials and Provides Business Update

$5.5 million financing that closed on April 2, 2026 together with $5.7 million in capital raised in Q1-2026...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 5/A - Annual statement of changes in beneficial ownership of securities: [Amend]

Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB